American gastroenterological association institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

Gastroenterology

Volumn 130, Issue 3, 2006, Pages 935-939

  Lichtenstein, Gary R ^{a,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac,ad}   Abreu, Maria T ^{b,e,s,v,ac,ae}   Cohen, Russell ^{c,e,f,i,j,o,t,v,y,aa,ae,af,ag,ah,ai}   Tremaine, William ^d,aa,ae,af  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Mayo Clinic   (United States)

^e Abbott Corporation   (United States)

^f Astra Zeneca Inc   (United States)

^g Axcan Corporation   (United States)

^h Berlex   (United States)

ⁱ CENTOCOR INC   (United States)

^j Elan   (United States)

^k Genetics Institute   (United States)

^l GLAXOSMITHKLINE   (United States)

^m Inkine Inc   (United States)

ⁿ Intesco Corporation   (United States)

^o ISIS Corporation   (United States)

^p Millenium Pharmaceuticals   (United States)

^q Otsuka Corporation   (Japan)

^r Proctor and Gamble Pharmaceut Div   (United States)

^s Prometheus Laboratories Inc   (United States)

^t Protein Design Labs   (United States)

^u Protomed Scientific   (United States)

^v Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^w Schering Plough Corporation   (Germany)

^x Serono   (United States)

^y Shire Pharmaceuticals   (United States)

^z Smith Kline Beecham Corporation   (United States)

^aa SOLVAY   (Belgium)

^ab Synta Pharmaceuticals   (United States)

^ac UCB New Medicines   (United States)

^ad Chemical and Screening Sciences   (United States)

^ae PROCTER AND GAMBLE COMPANY   (United States)

^af Kenwood ^*

^ag Kenwood   (United States)

^ah Gray and Rice Strategic Communications   (United States)

^ai Pfizer

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ANUS FISTULA; COLITIS; COLON CROHN DISEASE; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG RELEASE; DRUG USE; ENTERITIS; GASTROINTESTINAL DISEASE; HEALTH CARE ORGANIZATION; HUMAN; ILEOCECAL VALVE; MAINTENANCE THERAPY; MEDICAL SPECIALIST; PRIORITY JOURNAL; PROCTITIS; REVIEW; SIDE EFFECT; SPLEEN DISEASE; ULCERATIVE COLITIS;

EID: 33644855102     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.01.047     Document Type: Article

References (0)